Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.18 billion
- Book Value:
- Revenue TTM:
- $426.41 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
HUTCHMED DRC had its IPO on 2016-03-17 under the ticker symbol HCM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. HUTCHMED DRC has a staff strength of 1,280 employees.
Shares of HUTCHMED DRC opened at $12.63 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $12.28 - $12.66, and closed at $12.5.
This is a +3.05% increase from the previous day's closing price.
A total volume of 51,896 shares were traded at the close of the day’s session.
In the last one week, shares of HUTCHMED DRC have slipped by -2.5%.
HUTCHMED DRC's Key Ratios
HUTCHMED DRC has a market cap of $2.18 billion, indicating a price to book ratio of 3.0277 and a price to sales ratio of 5.9678.
In the last 12-months HUTCHMED DRC’s revenue was $426.41 million with a gross profit of $-271587000 and an EBITDA of $-399028992. The EBITDA ratio measures HUTCHMED DRC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, HUTCHMED DRC’s operating margin was -95.61% while its return on assets stood at -21.22% with a return of equity of -43%.
In Q4, HUTCHMED DRC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 12.9%.
HUTCHMED DRC’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into HUTCHMED DRC’s profitability.
HUTCHMED DRC stock is trading at a EV to sales ratio of 4.1435 and a EV to EBITDA ratio of -6.3845. Its price to sales ratio in the trailing 12-months stood at 5.9678.
HUTCHMED DRC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.03 billion
- Total Liabilities
- $353.90 million
- Operating Cash Flow
- Capital Expenditure
- $9.35 million
- Dividend Payout Ratio
HUTCHMED DRC ended 2023 with $1.03 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.03 billion while shareholder equity stood at $610.37 million.
HUTCHMED DRC ended 2023 with $0 in deferred long-term liabilities, $353.90 million in other current liabilities, 86478000.00 in common stock, $-971481000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $313.28 million and cash and short-term investments were $631.00 million. The company’s total short-term debt was $264,621,000 while long-term debt stood at $18.10 million.
HUTCHMED DRC’s total current assets stands at $839.89 million while long-term investments were $0 and short-term investments were $317.72 million. Its net receivables were $97.99 million compared to accounts payable of $71.12 million and inventory worth $56.69 million.
In 2023, HUTCHMED DRC's operating cash flow was $0 while its capital expenditure stood at $9.35 million.
Comparatively, HUTCHMED DRC paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
HUTCHMED DRC stock is currently trading at $12.5 per share. It touched a 52-week high of $21.28 and a 52-week low of $21.28. Analysts tracking the stock have a 12-month average target price of $46.7473.
Its 50-day moving average was $14.3 and 200-day moving average was $13.51 The short ratio stood at 8.91 indicating a short percent outstanding of 0%.
Around 41.3% of the company’s stock are held by insiders while 1687.5% are held by institutions.
Frequently Asked Questions About HUTCHMED DRC
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3′-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton’s tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.